Antiviral T cells protected, viable as off-the-shelf treatment for painful complication stem cells Kumar Jeetendra | May 2, 2021 Infusion of T cells targeting BKV resulted in rapid responses, with 67.7% of patients seeing a complete or partial improvement in symptoms after 14 days. This increased to 81.6% of patients after 28 days post-infusion. No cases of grade 3 or grade 4 graft versus host disease (GVHD) or other infusion-related toxicities occurred. Addressing a …
